Healthcare and Life Sciences Committee Meeting
The first panel features the work a task force has been doing on reviewing clauses in life science licensing transactions and offering guidance on how to ensure parties entering these transactions can more clearly focus on optimizing the value of the arrangement and avoiding unnecessary downstream conflicts and disruptions. The second panel examines the interesting issues in life science arbitrations around the application of mandatory law, such as patent law and regulations. What implications for decision-making and enforceability might these “mandatory” rules pose to parties, advocates, and arbitrators in resolving these disputes?
Panel I: “Mitigating Risks in Life Sciences Transactions – a review of the work of the Task Force.”
Panel II: “How Mandatory Should Mandatory Law Be – Considerations for Arbitrating Life Science Disputes.”